Entropy Technologies LP Purchases 9,467 Shares of Doximity, Inc. (NASDAQ:DOCS)

Entropy Technologies LP raised its position in shares of Doximity, Inc. (NASDAQ:DOCS) by 162.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,302 shares of the company’s stock after purchasing an additional 9,467 shares during the period. Entropy Technologies LP’s holdings in Doximity were worth $817,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. UMB Bank n.a. raised its holdings in shares of Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after acquiring an additional 235 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Doximity by 324.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after purchasing an additional 603 shares in the last quarter. Morse Asset Management Inc bought a new stake in shares of Doximity in the 3rd quarter valued at about $46,000. GAMMA Investing LLC lifted its position in shares of Doximity by 40.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock worth $63,000 after purchasing an additional 412 shares during the period. Finally, Covestor Ltd boosted its stake in shares of Doximity by 441.9% during the third quarter. Covestor Ltd now owns 1,680 shares of the company’s stock valued at $73,000 after purchasing an additional 1,370 shares in the last quarter. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 37.40% of the stock is currently owned by insiders.

Doximity Stock Performance

Shares of DOCS opened at $74.91 on Wednesday. The stock has a 50-day moving average of $56.61 and a two-hundred day moving average of $46.63. The stock has a market cap of $13.98 billion, a P/E ratio of 74.91, a P/E/G ratio of 4.61 and a beta of 1.39. Doximity, Inc. has a one year low of $22.96 and a one year high of $85.21.

Analysts Set New Price Targets

A number of brokerages recently commented on DOCS. Truist Financial boosted their price objective on shares of Doximity from $35.00 to $49.00 and gave the stock a “hold” rating in a research note on Thursday, November 14th. Leerink Partnrs upgraded Doximity from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley upgraded Doximity from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $33.00 to $53.00 in a research note on Thursday, November 14th. Leerink Partners raised shares of Doximity from a “market perform” rating to an “outperform” rating and increased their price target for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Finally, Barclays lifted their price objective on shares of Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.22.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.